A Multicenter, Phase 2b/c, Open-label, Randomized, Dose-finding Trial to Evaluate the Safety and Efficacy of a 4 Month Regimen of OPC-167832 in Combination With Delamanid and Bedaquiline in Subjects With Drug-susceptible Pulmonary Tuberculosis in Comparison With Standard Treatment
Latest Information Update: 11 Jul 2024
Price :
$35 *
At a glance
- Drugs Bedaquiline (Primary) ; Delamanid (Primary) ; Quabodepistat (Primary) ; Ethambutol; Isoniazid; Pyrazinamide; Rifampicin
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 27 Jun 2024 Status changed from active, no longer recruiting to completed.
- 21 Mar 2024 According to an Otsuka Pharmaceutical Development & Commercialization Media Release, full results of this phase 2b/c, randomized trial are expected by the end of 2024.
- 21 Mar 2024 According to an Otsuka Pharmaceutical Development & Commercialization Media Release, this study is being held across six clinical research sites in South Africa.